Merck decides it's smart to leave ALEC

Another drug company is bailing on ALEC, the group that gets business leaders together with mostly Republican state lawmakers to write so-called model legislation, generally around business. The American Legislative Exchange Council has been in the spotlight this year for support of tougher voter ID laws and self-defense gun laws. A Merck ($MRK) spokeswoman tells NJ.com that Merck reviews its memberships each fall and decides which ones meet its budget and policy priorities, and ALEC didn't make the cut this year. Johnson & Johnson ($JNJ) dropped its membership in June. Pfizer found itself the subject of criticism earlier this year for its membership in ALEC, which has been accused of inappropriate lobbying. Story | More

Suggested Articles

How long can one infusion of CAR-T drug Yescarta continue helping patients with refractory large B-cell lymphoma? Pretty long, Gilead showed Saturday.

AbbVie and Roche have fielded their fair share of questions about how well their fixed-duration regimen of Venclexta and Rituxan can keep CLL at bay.

Saturday, AstraZeneca revealed more of the data that convinced the FDA to green-light Calquence in previously untreated chronic lymphocytic leukemia.